You have been diagnosed with breast cancer in one breast. Your surgeon may ask: should you also remove the healthy breast? This is contralateral prophylactic mastectomy, or CPM. For most women, the right choice depends on your personal risk. Bilateral robotic nipple-sparing mastectomy is making this decision more manageable for many high-risk women.
The short answer: CPM reduces the risk of a future cancer in the opposite breast by more than 90% in women with a BRCA1 or BRCA2 gene variant. Bilateral robotic surgery achieves the same cancer-risk reduction. Small armpit incisions keep the nipple and minimize chest scarring. This changes many high-risk women's thinking about CPM.
What is contralateral prophylactic mastectomy?
Contralateral means the opposite side. Prophylactic means preventive. CPM removes the unaffected breast to lower the risk of a second primary breast cancer developing in the future. It does not treat existing cancer in that breast - it reduces risk while you treat the affected side.
CPM is different from bilateral mastectomy done when cancer is found in both breasts at diagnosis. Women choose CPM when they have cancer in only one breast but want to lower the lifetime risk of a new cancer in the other breast.
Who tends to consider CPM?
CPM is not recommended for all women with breast cancer. Most guidelines do not suggest it for women with average risk and no genetic or family history factors. According to the National Cancer Institute, preventive breast surgery is mainly for women with clearly higher lifetime risk.
Women who most often discuss CPM with their surgeon include those who:
- Carry a pathogenic variant in the BRCA1 or BRCA2 gene
- Have a strong family history of breast or ovarian cancer across multiple relatives or generations
- Were diagnosed at a younger age - typically under 40
- Have been diagnosed with certain higher-risk breast cancer subtypes
- Have very dense breast tissue that makes routine surveillance with mammography more difficult
BRCA status matters. A 2021 review published via PubMed Central found that BRCA carriers with breast cancer had a contralateral breast cancer rate of 23.7% over follow-up, compared with 6.8% in non-carriers. This near-fourfold difference is why oncologists and surgeons raise CPM as an option for this group.
If you have not had BRCA testing, ask your oncologist for a referral to a clinical genetics service. You need to know your gene status to make this decision. Your GP or breast surgeon can arrange a referral.
What does the evidence say about risk and survival?
CPM's risk-reduction evidence in BRCA carriers is strong. One study published via PubMed Central (Metcalfe et al.) found that CPM reduced contralateral breast cancer risk by approximately 91% in BRCA1 and BRCA2 carriers. A later systematic review and meta-analysis also available via PubMed Central reported a comparable figure of around 93%.
Overall survival is more complex. Some studies suggest CPM improves survival in younger BRCA carriers. Others do not find a significant survival benefit once you factor in chemotherapy, targeted therapy, or hormone therapy. CPM reduces risk in the opposite breast. Systemic treatment addresses overall risk. Your oncologist can explain what each contributes to your situation.
For women without higher genetic risk, there is no clear survival benefit from CPM, which is why guidelines focus this conversation on higher-risk groups. If you are unsure about your risk, get a formal genetic risk assessment first.
How does bilateral robotic surgery change the equation?
Traditional bilateral mastectomy uses incisions across the front of both breasts. Even with immediate reconstruction, visible scars across both breasts are common. For many women, the idea of scarring a healthy breast is a real barrier to CPM - even when the risk case for it is clear.
Bilateral robotic nipple-sparing mastectomy offers a different result. The surgeon uses small armpit incisions and robotic tools to remove breast tissue while keeping the nipple, areola, and skin. One study published via PubMed Central (Toesca et al.) confirmed the technique is safe with low complication rates. A later study of 266 procedures published on PubMed reported a 4.14% complication rate and a 98.3% three-year overall survival rate.
Women report good results. A review of bilateral prophylactic mastectomy with reconstruction available via PubMed Central found that keeping the nipple-areola complex led to higher satisfaction with the breasts, better mental health, and better sexual well-being over time. These outcomes matter over decades, not just the first weeks after surgery. To understand what the robotic nipple-sparing approach involves compared with skin-sparing options, see our guide to robotic nipple-sparing vs skin-sparing mastectomy outcomes.
How do the main options compare?
| Factor | No CPM (treat one breast only) | Traditional bilateral mastectomy | Bilateral robotic nipple-sparing mastectomy |
|---|---|---|---|
| Contralateral cancer risk in BRCA carriers | Remains at approx. 23.7% over follow-up | Reduced by approx. 91-93% | Reduced by approx. 91-93% (same oncological goal) |
| Nipple and skin preservation | Depends on technique used for the affected breast | Possible but more limited via open incisions | More consistently achievable via small armpit incisions |
| Visible scarring on the chest | Depends on unilateral approach chosen | Typically visible scars across both breasts | Incisions in armpit; minimal visible chest scarring |
| NHS availability in the UK | Widely available | Available for eligible patients via breast unit | Very limited on NHS; mainly specialist private or international centres |
| Patient-reported body image satisfaction | Variable; depends on unilateral outcome | Improved after reconstruction; affected by chest scarring | Higher when nipple is preserved; supported by patient-reported outcome research |
Cancer-risk-reduction figures from Metcalfe et al., PubMed Central and 2021 meta-analysis, PubMed Central. BRCA carrier contralateral risk from Cavanagh et al., PubMed Central. Patient satisfaction data from bilateral prophylactic mastectomy review, PubMed Central. NHS availability is a qualitative clinical assessment; individual outcomes vary.
Both the robotic and open approaches achieve the same cancer-risk reduction in the opposite breast. Where they differ is how your body looks and feels afterwards. If scarring or nipple loss made you hesitant about CPM, the robotic option changes things.
Why this is reshaping the CPM conversation for UK women
For many years, the physical cost of CPM felt too high to women who were otherwise healthy in that breast. Even when the numbers made a clear case, many women declined because of how traditional bilateral mastectomy looked on the body.
Bilateral robotic nipple-sparing mastectomy changes that. You can achieve more than a 90% reduction in contralateral cancer risk while keeping both nipples and avoiding visible chest scars. For many women, this is different from what CPM used to mean.
Candidacy matters. Not every woman can have robotic nipple-sparing mastectomy on both sides. If the tumor is close to the nipple, you had prior radiation, or your body type makes it risky, nipple preservation may not be safe. Our article on BRCA-positive women considering robotic prophylactic mastectomy covers who is eligible and what to ask your genetic counselor and breast surgeon.
What about reconstruction at the same time?
Bilateral robotic mastectomy is typically planned with immediate reconstruction. Options are implant-based reconstruction (silicone or saline implants placed at the same surgery) and autologous reconstruction using your own tissue - such as the DIEP flap (tissue from the lower abdomen). The best choice depends on your body type, whether you'll have radiation, and what you prefer for how you look. Our guide to immediate vs delayed reconstruction after robotic mastectomy covers the main choices in clear language.
Accessing bilateral robotic mastectomy in the UK
Robotic nipple-sparing mastectomy is not widely available on the NHS. Few centers have the equipment and trained teams, and bilateral robotic procedures for CPM are even rarer. For most UK women, options are a private UK hospital with a robotic breast program or surgery abroad at an accredited center.
Many UK women have surgery in India. Hospitals there offer bilateral robotic nipple-sparing mastectomy with immediate reconstruction done by experienced surgical teams. Some centers have female surgeons and female coordinators. Costs are lower than UK private hospitals. If you are considering this instead of your NHS plan, the Art of Healing Cancer team can review your case before you decide.
You can combine surgery abroad with UK treatment. Many women have surgery abroad and return to the UK for radiation, chemotherapy, or hormone therapy with their NHS or private oncology team. This works if your overseas surgeon and UK oncologist communicate clearly before you travel.
You can contact BreastCancer.One to explore whether bilateral robotic surgery fits your situation. Female coordinators can help you understand your options.
Questions worth raising with your specialist
- Has my BRCA status been formally assessed, and what does the result mean for my 10-year contralateral breast cancer risk?
- Am I a candidate for nipple-sparing mastectomy on the affected side, and would I also be suitable on the healthy side?
- Does my cancer subtype, grade, or hormone-receptor status affect whether CPM is advisable for me?
- Is bilateral robotic mastectomy available at this centre, and if not, where can I access it?
- Can reconstruction happen at the same operation, and which method suits my body type and adjuvant treatment plan?
- How does CPM affect my planned radiotherapy, chemotherapy, or hormone therapy schedule?
When to talk to your doctor
Talk to your breast surgeon or oncologist about CPM before your surgery date is set. If you have not had BRCA testing, ask for a referral to a clinical genetics service. If you feel the conversation has ended without fully discussing your personal risk, ask for a second opinion - it is standard in UK breast cancer care. You do not have to decide about CPM at your first appointment.
This article is for general information and not a substitute for medical advice. Always consult your oncologist or care team about your situation.